Canadian Companies Have Chance to Dominate Global Medical Cannabis Market.
Momentum Public Relations
Blog: March 21 2018
Tetra Bio-Pharma Receives FDA Orphan Drug Status for PPP001
Canadian Companies Have Chance to Dominate Global Medical Cannabis Market.
Grand View Research has predicted that the global medical marijuana market will reach US$55.8 billion by 2025.
When licensed medical marijuana producers first began to list on the Canadian stock exchanges they received sky high valuations.
Some analysts and producers looked beyond the domestic market and wondered if the legalization of marijuana in Canada would allow Canadian marijuana growers to take a dominant position in the global market as marijuana legalization rolled out around the world.
It now looks as if Canada stands a good chance to become a global leader in the development of cannabinoid-based drugs and the regulatory approvals that ensure their safety and efficacy.
The cannabinoid-based drug market is going to be huge. Grand View Research has predicted that the global medical marijuana market will reach US$55.8 billion by 2025.
A Bloomberg News story published in the Financial Post on December 28, 2017 explains why Canadian medical cannabis producers and drug companies are set to move onto the global stage.
The established use of medical cannabis in Canada and the legalization of recreational marijuana both play a part in this.
Canopy Growth CEO Bruce Linton was quoted in the story as saying that the theme for 2018 will be the globalization of medical cannabis. One of Canada’s first medical marijuana producers, Canopy already ships to Germany and has partnerships with companies in Australia, Spain and Jamaica.
In effect, Canada has first mover status on the international market and if domestic producers do the right things they stand a good chance of dominating the global market.
While medical cannabis is now being prescribed in a variety of jurisdictions, it is only being prescribed because of anecdotal evidence. There is no scientific proof that medical cannabis-based therapeutic treatments work. The pharmaceutical companies that succeed in providing regulatory approval backed by hard science stand to profit with a very large market share.
Canada is leading the way because while one might assume that research powerhouse the United States would be at the head of the line, American research is hamstrung by the fact that while legal in many states, it is not legal at the American federal level. This means that federal research funding is not available.
Against that backdrop Canadian biopharmaceutical research and development company Tetra Bio-Pharma, dedicated to becoming the first to prove the safety and efficacy of cannabis-based drugs, has received funding from the National Science and Research Council of Canada.
The company has already started a Phase 3 clinical study designed to prove the safety and efficacy of its flagship product, smokable PPP001, designed as a therapeutic treatment for chronic and cancer pain. The company believes that PPP001 will be on the market no later than 2019.
Canada’s ability to lead the international pack when it comes to the development of cannabis-based therapeutic drugs can be illustrated by two recent developments.
On March 14, 2018 Tetra Bio-Pharma announced that it had received “Orphan Drug Status” for PPP001, for the treatment of Complex Regional Pain Syndrome by the American FDA.
Orphan drug status is a designation used to encourage research into drugs for the treatment of rare diseases that affect only a small percentage of the population, 200,000. It provides a seven year marketing exclusivity for the orphan drug.
Tetra Bio-Pharma is a biopharmaceutical company dedicated to providing the science that will prove that medical cannabis-based drugs are safe and actually work.
Unless a dark horse dramatically emerges, Tetra Bio-Pharma will also be the first biopharmaceutical to be granted Health Canada and FDA approvals, which in return will grant the approved drugs a Drug Identification Number, DIN. DIN numbers allow the drug to be prescribed by doctors, sold by pharmacies and covered by insurance plans.
DIN numbers are the Holy Grail in pharmaceutical research. Once you have them your products are legal to market. Without a DIN number they can’t be sold.
Tetra has a pipeline of cannabis-based drugs under development and has recently created a veterinary division to create cannabis-based drugs for the lucrative cat and dog market.
The company has also just announced its first European foray with partner PS Innovations. PS Innovations manufactures Tetra’s trademarked RX Princeps Inhalation Device. Tetra announced on March 6, 2018 that PS Innovations will apply for CE Marking, a process that guaranties the product conforms to European regulations and can be sold in the European Economic Area where it will be listed as a Class 1 Medical Device.
Another indication that Canada stands a good chance of leading the medical cannabis world is the recent agreement between Sandoz Canada and licensed medical marijuana producer Tilray Inc. On March 19, 2018, Tilray announced that it had formed an exclusive partnership with Sandoz Canada to develop non-smokable cannabis-based therapeutic drugs delivered through gel caps or lotions.
Sandoz is owned by Novatis and the agreement represents big pharma’s first venture into developing cannabinoid-based therapeutic treatments.
Pascal Biosciences discovered certain cannabinoids that help our immune system kill tumor cells.
Canopy Growth also has a medical division that holds a number of patents. If Canada can develop the momentum that comes with first mover status there is a good chance that it can dominate the global medical cannabis market.
- Published in Blog
Equitorial Encounters 36m Pegmatite at Cat Lake Lithium Property, Manitoba
Momentum Public Relations
Press Release: March 21 2018
Equitorial Exploration Corp. (TSX-V: EXX, Frankfurt: EE1, OTCQB: EQTXF) (“Equitorial” or “Company”) is pleased to report that drill hole CT-18-02 encountered approximately 36 meters of a spodumene bearing pegmatite in core at its 100%-owned Cat Lake Lithium Property in SE Manitoba directly, adjacent to the Cat Lake Mineral Project owned by Quantum Minerals Corp.
Drill Program Update
Drill hole CT-18-02 is the second drill hole of the Company’s aggressive 1,100 meter drill program. Drill hole CT-18-02 was positioned to intersect a possible extension of the Irgon Pegmatite system, presently being explored by QMC Quantum Minerals to the west of the company’s claims.
The drill hole encountered approximately 36 meters of a spodumene bearing pegmatite (true width not determined at this time) at a depth of 126 meters downhole or 90 meters below the surface.
The hole was collared approximately 200 meters southeast of the last surface exposure of the Irgon Pegmatite. Prior to being drilled, this pegmatite was buried with no surface expression.
The next few drill holes will focus on defining the orientation and extent of the newly discovered pegmatite.
The company is presently in the process of sampling the new pegmatite and will announce assay results once they are received and reviewed.
The drill program is headed up by Carey Galeschuk. P. Geo, a consulting geologist with extensive experience in lithium bearing pegmatites. He also serves as Qualified Person for the purpose of National Instrument 43-101.
CEO Jack Bal, comments
” The discovery of this new pegmatite at depth may be a part of the Irgon Pegmatite system or represent a totally new pegmatite system. Either scenario adds significant value to Equitorial’s Cat Lake Property and to the Company as a whole. We will continue to enlarge our understanding of this new discovery .”
Cat Lake Lithium Property Highlights
- – Property situated directly east and along strike of Quantum Minerals’ Cat Lake Mineral Project (previously Irgon Lithium Mine) . During 1956-1957, t he Irgon Mine was an underground mining operation for spodumene (one of the hard rock sources for Li). The pegmatite had an historic estimate of 1.25 million tons of ore grading 1.51% Li20 (Mineral Inventory File No. 221).- Equitorial claim block 150 m from south end of Irgon Lithium Mine shaft and approximately 93m east of the last exposed outcrop of the Irgon Pegmatite
– 48 feet of spodumene bearing quartz were drilled in 1948 on the company’s present claims but not followed up at the time (Manitoba Assessment File 98073 – not 43-101 compliant )
– Property approximately 180km northeast of Winnipeg, Manitoba
– Excellent infrastructure – Provincial Highway 314 in southeast Manitoba cuts through the property
Please click for maps of the claims: http://equitorialexploration.com/wp-content/uploads/2018/01/Cat-Lake-Claims-Maps-3.pdf
QMC Quantum Minerals Cat Lake Mineral Project
QMC Quantum Minerals Corp News Release September 7, 2017 reported:
“Between 1953-1954, the Lithium Corporation of Canada Limited drilled 25 holes into the Irgon Dike and reported a historical resource estimate of 1.2 million tons grading 1.51% Li20 over a strike length of 365 meters and to a depth of 213 meters (Northern Miner, Vol. 41, no.19, Aug. 4, 1955, p.3). This historical resource is documented in a 1956 Assessment Report by Bruce Ballantyne for the Lithium Corporation of Canada Ltd. (Manitoba Assessment Report No. 94932). This historical estimate is believed to be based on reasonable assumptions and the company/QP has no reason to contest the document’s relevance and reliability.”
The property lies within the east-trending Mayville-Cat-Euclid Greenstone Belt (“MCEGB”) located along the northern contact of the Maskwa Lake Batholith. This northern greenstone belt has a similar structural geological setting as the Bird River Greenstone Belt (“BRGB”) which is located along the southern contact of the same batholith, and is parallel to and approximately 18km to the south of the MCEGB. The property is located 20km north of the Tanco Mine Property. The
BRGB hosts the world-class Tanco rare element-bearing pegmatite dike as well as numerous other lithium bearing pegmatites. The Tanco Mine went into production in 1969 and produced tantalum, cesium and spodumene (lithium). It was previously North America’s largest and sole producer of spodumene (Li), tantalite (Ta) and pollucite (Cs).
About Equitorial Exploration Corp
Equitorial is aggressively developing four 100%-owned, high-potential, lithium projects in North America. The Little Nahanni Pegmatite Group (LNPG) is a 43-101 compliant, hard rock, lithium property in the NWT. The Cat Lake Lithium Property in Manitoba, Canada is directly adjacent to the Cat Lake Mineral Project, a highly prospective Lithium property. The Tule and Gerlach Lithium Brine Projects are located in lithium-rich Utah and Nevada within easy reach of the Tesla Gigafactory #1. All four projects have demonstrated highly encouraging grades.
For more information please visit: http://equitorialexploration.com/
On behalf of the Board of Directors
EQUITORIAL EXPLORATION CORP.
_____________________
Jack Bal, CEO and Director
For further information, please contact Jack Bal at 604-306-5285
FORWARD LOOKING STATEMENTS: This news release contains certain forward-looking statements within the meaning of Canadian securities laws, including statements regarding the Cat Lake, Tule, Gerlach and Little Nahanni Pegmatite Projects: statements pertaining to the ability of Equitorial Exploration Corp.(“EXX”); the potential to develop resources and then further develop reserves; the anticipated economic potential of the property; the availability of capital and finance for EXX to execute its strategy going forward. Forward-looking statements are based on estimates and assumptions made by EXX in light of its experience and perception of current and expected future developments, as well as other factors that EXX believes are appropriate in the circumstances. Many factors could cause EXX’s results, performance or achievements to differ materially from those expressed or implied by the forward looking statements, including: discrepancies between actual and estimated results from exploration and development and operating risks, dependence on early exploration stage concessions; uninsurable risks; competition; regulatory restrictions, including environmental regulatory restrictions and liability; currency fluctuations; defective title to mineral claims or property and dependence on key employees. Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Published in Equitorial Exploration, Uncategorized
Crystal Lake starts drilling at Nicobat
Momentum Public Relations
Press Release: March 21 2018
Diamond drilling has commenced at Crystal Lake Mining Corp.’s 100-per-cent-owned Nicobat project (nickel-cobalt-copper-precious metals) in the Rainy River district of Northwestern Ontario. In addition, the company has expanded its deep penetrating airborne electromagnetic survey from the originally planned 500 line kilometers to 850 line kilometers.
Richard Savage, Crystal Lake Mining CEO, stated: “The historic zone outlined at the Nico1 Property, combined with today’s new technologies and a much better understanding of nickel sulfide deposits, gives us confidence that we’re on track for a new discovery in this under-explored district. We’re continuing to develop our pipeline of exceptional nickel sulfide targets across the 50 sq. km project area, and we look forward to providing regular updates through Phase 1 of this program.”
The first two holes at the Nico1 Property will undercut the historic zone to targeted depths of at least 400 meters and are designed to explore beneath the near-surface disseminated and breccia style magmatic sulfide mineralization. The boreholes will provide an ideal geophysical platform for Lamontagne Geophysics’ borehole electromagnetic survey work to detect nearby conductive targets that may correspond to semi-massive and massive sulfides.
Qualified Person
The technical information in this news release has been reviewed and approved by Dr. Peter C. Lightfoot, P.Geo., and Dr. Elisabeth Ronacher, P.Geo., who are both Qualified Persons responsible for the scientific and technical information in this news release under National Instrument 43-101 standards. Certain technical information in this news release has previously been disclosed by Crystal Lake Mining in its public disclosure record. Readers should refer to Crystal Lake Mining’s full public disclosure record at www.sedar.com.
About Crystal Lake Mining
Crystal Lake Mining is a Canadian-based junior exploration company focused on building shareholder value through the discovery of new magmatic nickel sulfide deposits using technical excellence in exploration target development.
- Published in Crystal Lake Mining
Albert Mining Inc. Acquires 9 Mining Titles at lac Guillaume close to Shefferville, Quebec
Momentum Public Relations
Press Release: March 20 2018
Albert Mining Inc . (“Albert” or “Corporation”) (TSX-V: AIIM), a mining exploration company and a leader in the use of Artificial Intelligence (AI) and advanced knowledge-extraction techniques in the mining sector, is pleased to announce the signing of a purchase agreement with 9248-7792 Quebec Inc. (“seller”) to acquire nine mining titles at Lac Guillaume, 30 km west of Shefferville in the province of Quebec.
Under the terms of the agreement, Albert will issue 150,000 common shares of its share capital to the seller, at a deemed price of $0.075 per share, in payment for the acquisition of the assets and will grant a 1% NSR. Albert may, at any time, buy back 0.5% NSR by paying $500,000 to the seller. Should the seller receive an offer from a third party to purchase the full or a portion of the NSR, Albert must be immediately notified in writing and must receive a copy of the offer. Albert will have the right of first refusal within 60 days following reception of the offer or buy back the NSR as per the terms and conditions stipulated in the offer received from the third party.
The transaction is subject to terms and conditions such as receipt of all required regulatory approvals, including the approval of the TSX Venture Exchange. All monies quoted in this news release shall be stated and paid in lawful money of Canada.
About Albert Mining Inc.
Albert is a junior mining exploration company with an extensive portfolio of gold, copper and diamond properties in Quebec. Albert also recently acquired assets from DIAGNOS Inc.’s mining division, including the Computer Aided Resources Detection System (“CARDS”). Albert can count on a multidisciplinary team that includes professionals in geophysics, geology, Artificial Intelligence, and mathematics. The Company’s objective is to develop a new royalty stream by significantly enhancing and participating in the exploration success rate of mining.
For further information, please contact:
Michel Fontaine
President and CEO of Albert Mining Inc.
Telephone: 514-994-5843
Fax: 613-422-0773
Email: michel@albertmining.com
Website: www.albertmining.com
Albert Mining-Powered by Artificial Intelligence
Additional information about the Company is available under Albert’s profile on SEDAR at www.sedar.com .
- Published in Albert Mining
Tetra Bio-Pharma Added to Leading Cannabis ETF: Horizons Marijuana Life Sciences Index
Momentum Public Relations
Press Release: March 20 2018
Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has been added to the Horizons Marijuana Life Sciences Index (HMMJ) managed by Horizons ETFs Management (Canada) Inc.
HMMJ was the first and is the world’s largest ETF offering direct exposure to North American-listed securities that are involved with marijuana bioengineering and production. The HMMJ portfolio recently expanded to include ten new constituents, including Tetra.
“This is a very positive sign for our shareholders,” says Bernard Fortier, CEO of Tetra. “Having Horizons trusting us after completing a $11.5 million bought deal and in the process of a $ 4.5 million private placement is a strong message of confidence. Our clinical approach and pipe-line of products are unique and being added to this index reinforces the credibility of our approach to the financial community.”
HMMJ is an index (or passively managed) ETF, which seeks to replicate, to the extent possible, the performance of the North American Marijuana Index (the “Index”), net of expenses. The Index is designed to provide exposure to the performance of a basket of North American publicly listed life sciences companies with significant business activities in the marijuana industry. The Index selects from a current universe of companies that have operations that may include one or more of biopharmaceuticals, medical manufacturing, distribution, bio-products and other ancillary businesses related to the marijuana industry.
More info on: https://www.horizonsetfs.com/news/Press-Release/Horizons-ETFs-Completes-Rebalance-of-its-Marijuana
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.
More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Corporation believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Corporation’s ability to control or predict, that may cause the actual results of the Corporation to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the failure to obtain sufficient financing to execute the Corporation’s business plan; the success of the Rx Princeps™product offering and inhalation device; guidance on expected sales volumes associated with the Rx Princeps™product offering and inhalation device; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Corporation’s public disclosure record on file with the relevant securities regulatory authorities. Although the Corporation has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(438) 899-7575
For investors information, please contact:
investors@tetrabiopharma.com
(438) 504-5784
- Published in Tetra Bio Pharma
St-Georges Retains Gravitas Securities Inc. as Strategic Financial Advisors
Momentum Public Relations
Press Release: March 20 2018
St-Georges Eco-Mining Corp. (CSE: SX) (OTC: SXOOF) (FSE: 85G1) is pleased to announce that it has retained the services of Gravitas Securities Inc. to act as financial advisors to St-Georges and its related entities.
Gravitas will be tasked with assisting ZeU Crypto Networks Inc., St-Georges wholly-owned subsidiary, which is currently in the process of acquiring all the intellectual properties of Tiande, a developer of permission-based blockchain protocol with BigData connectivity. Gravitas will provide a number of services to ZeU including providing capital markets intelligence & guidance, financial & operational analysis of the company, and recommendations on capital requirements and strategic business decisions.
“With its contingent of Sino-Canadian personnel able to review our technology and business legal documentation in mandarin and the positive approach of the firm toward disruptive blockchain technologies, Gravitas is an excellent match for us. Their involvement should help us accelerate our financing effort with other securities firms and institutional investors. We also welcome their expertise to assist us for any corporate actions that might be undertaken in the coming months by the company” commented ZeU President Frank Dumas.
About Gravitas
Gravitas Securities is a leading wealth management and capital markets firm comprised of tactical individuals known for their sophisticated sector expertise, commitment to excellence, and a global platform committed to integration and innovation. Gravitas provides a wide range of investment services for retail and corporate clients globally with offices in Toronto and Vancouver, and is represented in the United States through its FINRA representative, Gravitas Capital International, in New York.
Gravitas Securities Inc. is a member of IIROC and CIPF.
ZeU Crypto Networks welcomes Lord Razzall as a director of the corporation
ZeU is pleased to welcome Lord Edward Timothy Razzall on its board of directors. Lord Razzall is a member of the British Parliament’ House of Lords and a Commander of the British Empire (CBE). Baron Razzall has been co-chair of the Liberal Democrat Parliamentary Committee on Business, Innovation and Science. He has over 35 years’ corporate finance experience and has developed a reputation for his expertise in multinational and cross border transactions. He was until recently the Liberal Democrat spokesman on Trade and industry and he’s now the Lords spokesman for manufacturing. He is currently Co-Chair of the Liberal Democrat Parliamentary Party Committee on Business, Innovation and Skills. Lord Razzall studied at Oxford University and qualified as a solicitor in 1969. ZeU expect to leverage Tim’s experience and interest in regulations, governance, monetary policies, intellectual property and corporate finance to its advantage.
ON BEHALF OF THE BOARD OF DIRECTORS
“Frank Dumas”
FRANK DUMAS, PRESIDENT & CEO
About St-Georges
St-Georges is developing new technologies to solve the some of the most common environmental problems in the mining industry.
The Company controls directly or indirectly, through rights of first refusal, all of the active mineral tenures in Iceland. It also explores for nickel on the Julie Nickel Project & for industrial minerals on Quebec’s North Shore and for lithium and rare metals in Northern Quebec and in the Abitibi region. Headquartered in Montreal, St-Georges’ stock is listed on the CSE under the symbol SX, on the US OTC under the Symbol SXOOF and on the Frankfurt Stock Exchange under the symbol 85G1.
- Published in St-Georges Eco-Mining
Equitorial Drilling at 100%-Owned Cat Lake Lithium Property, Manitoba
Momentum Public Relations
Press Release: March 19, 2018
Equitorial Exploration Corp. (TSX-V: EXX, Frankfurt: EE1, OTCQB: EQTXF) (“Equitorial” or “Company”) is pleased to report that the Company has drilled and logged the first hole of its aggressive 1,100 meter drill program at its 100%-owned Cat Lake Lithium Property directly adjacent to the Cat Lake Mineral Project owned by Quantum Minerals Corp.
Drill Program Summary
- – 1,100 m aggressive drill program of several holes
– First hole drilled and logged
– Three areas of interest:
- – Eastward extension of Quantum Minerals’ Irgon Pegmatite presently being explored by Quantum Minerals
– Follow up of 1948 drill hole reported to have encountered 48 feet (~14.63 m) of spodumene ( Manitoba Government assessment file 98073 – not 43-101 compliant ) . No additional drilling in the area was completed.
– Skarn associated with the Cat Lake Mine/Lithium Corp Cat Lake Mine – minimal information on the old mine site
– The drill program is headed up by Carey Galeschuk. P. Geo, a consulting geologist with extensive experience in lithium bearing pegmatites. He also serves as Qualified Person for the purpose of National Instrument 43-101.
- – Eastward extension of Quantum Minerals’ Irgon Pegmatite presently being explored by Quantum Minerals
Cat Lake Lithium Property Highlights
- – Property situated directly east and along strike of Quantum Minerals’ Cat Lake Mineral Project (previously Irgon Lithium Mine) . During 1956-1957, t he Irgon Mine was an underground mining operation for spodumene (one of the hard rock sources for Li). The pegmatite had an historic estimate of 1.25 million tons of ore grading 1.51% Li20 (Mineral Inventory File No. 221).
– Equitorial claim block 150 m from south end of Irgon Lithium Mine shaft and approximately 93m east of the last exposed outcrop of the Irgon Pegmatite and approximately 122 m along
– 48 feet of spodumene bearing quartz were drilled in 1948 – not followed up at the time (Manitoba Assessment File 98073 – not 43-101 compliant )
– Property approximately 180km northeast of Winnipeg, Manitoba
– Excellent infrastructure – Provincial Highway 314 in southeast Manitoba cuts through the property
Please click for a maps of the claims: http://equitorialexploration.com/wp-content/uploads/2018/01/Cat-Lake-Claims-Maps-3.pdf
Cat Lake Mineral Project
QMC Quantum Minerals Corp News Release September 7, 2017 reported:
“Between 1953-1954, the Lithium Corporation of Canada Limited drilled 25 holes into the Irgon Dike and reported a historical resource estimate of 1.2 million tons grading 1.51% Li20 over a strike length of 365 meters and to a depth of 213 meters (Northern Miner, Vol. 41, no.19, Aug. 4, 1955, p.3). This historical resource is documented in a 1956 Assessment Report by Bruce Ballantyne for the Lithium Corporation of Canada Ltd. (Manitoba Assessment Report No. 94932). This historical estimate is believed to be based on reasonable assumptions and the company/QP has no reason to contest the document’s relevance and reliability.”
The property lies within the east-trending Mayville-Cat-Euclid Greenstone Belt (“MCEGB”) located along the northern contact of the Maskwa Lake Batholith. This northern greenstone belt has a similar structural geological setting as the Bird River Greenstone Belt (“BRGB”) which is located along the southern contact of the same batholith, and is parallel to and approximately 18km to the south of the MCEGB. The property is located 20km north of the Tanco Mine Property. The BRGB hosts the world-class Tanco rare element-bearing pegmatite dike as well as numerous other lithium bearing pegmatites. The Tanco Mine went into production in 1969 and produced tantalum, cesium and spodumene (lithium). It was previously North America’s largest and sole producer of spodumene (Li), tantalite (Ta) and pollucite (Cs).
About Equitorial Exploration Corp
Equitorial is aggressively developing four 100%-owned, high-potential, lithium projects in North America. The Little Nahanni Pegmatite Group (LNPG) is a 43-101 compliant, hard rock, lithium property in the NWT. The Cat Lake Lithium Property in Manitoba, Canada is directly adjacent to the Cat Lake Mineral Project, a highly prospective Lithium property. The Tule and Gerlach Lithium Brine Projects are located in lithium-rich Utah and Nevada within easy reach of the Tesla Gigafactory #1. All four projects have demonstrated highly encouraging grades.
For more information please visit: http://equitorialexploration.com/
On behalf of the Board of Directors
EQUITORIAL EXPLORATION CORP.
_____________________
Jack Bal, CEO and Director
For further information, please contact Jack Bal at 604-306-5285
FORWARD LOOKING STATEMENTS: This news release contains certain forward-looking statements within the meaning of Canadian securities laws, including statements regarding the Tule, Gerlach and Little Nahanni Pegmatite Project: statements pertaining to the ability of Equitorial Exploration Corp.(“EXX”); the potential to develop resources and then further develop reserves; the anticipated economic potential of the property; the availability of capital and finance for EXX to execute its strategy going forward. Forward-looking statements are based on estimates and assumptions made by EXX in light of its experience and perception of current and expected future developments, as well as other factors that EXX believes are appropriate in the circumstances. Many factors could cause EXX’s results, performance or achievements to differ materially from those expressed or implied by the forward looking statements, including: discrepancies between actual and estimated results from exploration and development and operating risks, dependence on early exploration stage concessions; uninsurable risks; competition; regulatory restrictions, including environmental regulatory restrictions and liability; currency fluctuations; defective title to mineral claims or property and dependence on key employees. Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
- Published in Equitas Resources
Tetra Bio-Pharma Completes Acquisition of Remaining 20% Interest in PhytoPain Pharma Inc.
Momentum Public Relations
Press Release: March 19
Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation”) (TSX VENTURE:TBP)(OTCQB:TBPMF), today announced the completion of the previously announced acquisition of the remaining 20% interest in its PhytoPain Pharma Inc. subsidiary (the “Transaction”) from entities controlled by André Rancourt, Chairman of the Board of Directors of the Corporation, and Guy Chamberland, Chief Scientific Officer of the Corporation (collectively, the “Sellers”).
“The Transaction is an important milestone for Tetra Bio-Pharma and all our stakeholders,” said Bernard Fortier, Tetra’s CEO. “It allows Tetra to gain 100% control of PhytoPain Pharma, a key asset in the development of our pipeline of cannabinoid-based drugs and gives Tetra full flexibility to enter into other partnerships or agreements in the future.”
The purchase price for the Transaction was comprised of a combination of cash, promissory notes and common shares of Tetra, some of which will be released to the Sellers upon the achievement of key milestones. The terms of the Transaction are detailed in the Corporation’s news release dated January 2, 2018 which is available on SEDAR under the Corporation’s profile. The Corporation used $500,000 out of the proceeds from the recently completed bought deal offering to repay a portion of the principal amount owing to the Sellers under the promissory notes.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.
More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Corporation believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Corporation’s ability to control or predict, that may cause the actual results of the Corporation to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the failure to obtain sufficient financing to execute the Corporation’s business plan; the success of the Rx Princeps™product offering and inhalation device; guidance on expected sales volumes associated with the Rx Princeps™product offering and inhalation device; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Corporation’s public disclosure record on file with the relevant securities regulatory authorities. Although the Corporation has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(438) 899-7575
For investors information, please contact:
investors@tetrabiopharma.com
(438) 504-5784
- Published in Tetra Bio Pharma
Alliance Mining Has Commenced Drilling on its 100% Owned Packsack Gold Property in Bissett Gold Camp, Manitoba
Momentum Public Relations
Press Release: March 16
Alliance Mining Corp. (TSXV: ALM) has commenced drilling on its Packsack gold property, which forms part of the company’s Red Rice Lake gold project, is located in Manitoba’s Bissett gold camp, close to the town of Bissett.
InvestmentPitch Media has produced a “video” which describes this news. If this link is not enabled, please visit www.InvestmentPitch.com and enter “Alliance Mining” in the search box.
Cannot view this video? Visit:
http://www.investmentpitch.com/video/0_hro4doj7/Alliance-Mining-TSXVALM-Drilling-commenced-on-its-Packsack-gold-property
Alliance has an option to acquire 100% of the Red Rice Lake gold property, located in the centre of Bissett gold camp in Manitoba, Canada. The Red Rice Lake gold property claims are located within the Archean Rice Lake greenstone belt in southeastern Manitoba, a belt forming part of the Uchi sub province, which includes the Red Lake and Pickle Crow belts in Northwestern Ontario.
The approximately 1,000 metre drill program will consist of at least 3 holes, 2 of which will target an area under the known mineralization, plus a shorter hole to target the upper part of the Big Dome Vein, to confirm the grade/width f the known mineralization.
The Packsack property hosts several gold-bearing veins within a conjugate fracture set adjacent to the Red Rice shear zone. The structural control on veining at the Packsack property is similar to that at the True North Mine, 4 km northeast, operated by Klondex Mines Ltd.
This is the first significant drill program to test under the 500 foot or 152 metre level exploration drift on the Packsack property. Previous exploration, completed between 1936 and 1940, focused on the Big Dome Vein, with a shaft to 525 feet (160 metres) along with 2,867 feet (874 metres) of drifting and crosscutting on 4 levels down to 500 feet (152 metres).
Wynne Mining Services has been contracted to undertake the drill program, which will be supervised by Alliance’s consulting geologist William C. Hood, P.Geo., who has four decades of mineral exploration experience and has supervised multiple drill and exploration programs in the Bissett gold camp.
Alliance is actively seeking to expand its presence in the Bissett Gold camp through future property acquisitions and/or potential joint venture exploration partnerships with neighbouring companies.
For more information, please visit the company’s website www.alliancemining.com, contact Antony Claydon, Investor Relations, at 604-445-5421 or email ir@alliancemining.com.
About InvestmentPitch Media
Investmentpitch Media leverages the power of video, which together with its extensive distribution, positions a company’s story ahead of the 1,000’s of companies seeking awareness and funding from the financial community. The company specializes in producing short videos based on significant news releases, research reports and other content of interest to investors.
CONTACT:
InvestmentPitch Media
Barry Morgan, CFO
bmorgan@investmentpitch.com
- Published in Alliance Mining
Tetra Bio-Pharma Inc. Announces a Non-Brokered Private Placement
Momentum Public Relations
Press Release: March 16 2018
Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced that it is conducting a non-brokered private placement of up to 4,500,000 units at a price of $1.00 per unit for aggregate gross proceeds of up to $4,500,000.
Each unit will consist of one common share (a “Common Share”) in the Company and one warrant (a “Warrant” and collectively the “Warrants”). Each Warrant will entitle the holder thereof to acquire one Common Share at a price of $1.30, for a period of 36 months from the closing date.
The private placement is expected to close on or about March 31st, 2018.
The securities issued pursuant to the private placement will be subject to a four-month hold period from the closing date. Completion of the private placement remains subject to the receipt of all necessary regulatory approvals, including the approval of the TSX Venture Exchange.
The Company intends to use the net proceeds of the Offering to advance the Company’s Phase 3 trial for PPP001 and other clinical trials, to effect the repayment of indebtedness, for the support of its commercial efforts and for general corporate and working capital purposes.
The TSX Venture Exchange Inc. has not approved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
The securities described herein have not been, and will not be, registered under the U.S. Securities Act or any state securities laws, and accordingly, may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities requirements or pursuant to exemptions therefrom. This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.
More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Corporation believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Corporation’s ability to control or predict, that may cause the actual results of the Corporation to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the failure to obtain sufficient financing to execute the Corporation’s business plan; the success of the Rx Princeps™product offering and inhalation device; guidance on expected sales volumes associated with the Rx Princeps™product offering and inhalation device; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Corporation’s public disclosure record on file with the relevant securities regulatory authorities. Although the Corporation has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(438) 899-7575
For investors information, please contact:
investors@tetrabiopharma.com
(438) 504-5784
- Published in Tetra Bio Pharma